SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

DWTX says Halneuron shows durable efficacy in chemotherapy neuropathic pain

DWTX’s Halneuron, a selective NaV1.7 inhibitor, is described as targeting chemotherapy-induced neuropathic pain with durable efficacy and strong tolerability in clinical trials. Company says synthetic TTX manufacturing supports supply and IP, with phase III and NDA milestones planned.

DWTX

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories